Document:

--DRAFT ONLY--

RESOLUTION OF THE SHAREHOLDERS

OF

ZENDEX HOLDINGS INC.

The following is a true copy of the resolution duly adopted by the Majority of the Shareholders of the Corporation at a special meeting, notice to this meeting having been waived, held this 27th day of May, 2016

 

WHEREAS there has been presented to and considered by this meeting a Motion to effectuate a new Board of Directors of the Company; 

NOW THEREFORE BE IT RESOLVED that the majority of shareholders having considered this matter, and having opened the floor to all those who voice a preference in the issue and pursuant to NRS 78.320, have overwhelmingly decided and RESOLVED that we have elected: 

Wei Chi Lim as Director 

The Above qualified Director, having been nominated, has accepted his position as DIRECTOR of the Company. 

Said Motion is hereby passed and the corporate books, records and the Company shall file this Resolution in the corporate records. 

Dated: 27th, May, 2016

/s/ Wei Chi Lim

Wei Chi Lim, 

on behalf of the Majority ShareholdersRESIGNATION OF

RESIGNATION OF

THE BOARD OF DIRECTORS

OF

ZENDEX HOLDINGS, INC.

The following is a true copy of the resolution duly adopted by the Board of Directors of the Corporation at a special meeting, notice to this meeting having been waived, held on May 25th, 2016

The Board of Directors who were present for this meeting & took active part therein were: 

Josh Turner

Alex Demitriev

WHEREAS there has been presented to and considered by this meeting a Motion to formally RESIGN and renounce all further corporate designation or affiliation with Zendex Holdings, Inc.; 

NOW THEREFORE BE IT RESOLVED that the corporation having considered this matter, has opened the floor to all those who voice a preference in the issue, and pursuant to NRS 78.320 has decided unanimously and RESOLVED that: I Alex Demitriev do hereby formally RESIGN, and sever any and all officials ties, duties, obligations or liabilities regarding Zendex Holdings, Inc. and do, by affixing, my signature hereto, officially as my last corporate act, DO HEREBY RESIGN. 

The Director of the corporation, by affixing his signature hereto, does hereby formally resign, and shall allow the new Board to choose its Directors at a time and place of its choosing.  

DATED:  May 25th, 2016

/s/ Alex Demitriev

Alex Demitriev, Director, CFO 

Zendex Holdings, Inc.RESIGNATION OF

RESIGNATION OF

THE BOARD OF DIRECTORS

OF

ZENDEX HOLDINGS, INC.

The following is a true copy of the resolution duly adopted by the Board of Directors of the Corporation at a special meeting, notice to this meeting having been waived, held on May 25th, 2016

The Board of Directors who were present for this meeting & took active part therein were: 

Josh Turner

Alex Demitriev

WHEREAS there has been presented to and considered by this meeting a Motion to formally RESIGN and renounce all further corporate designation or affiliation with Zendex Holdings, Inc.; 

NOW THEREFORE BE IT RESOLVED that the corporation having considered this matter, has opened the floor to all those who voice a preference in the issue, and pursuant to NRS 78.320 has decided unanimously and RESOLVED that: I Josh Turner do hereby formally RESIGN, and sever any and all officials ties, duties, obligations or liabilities regarding Zendex Holdings, Inc. and do, by affixing, my signature hereto, officially as my last corporate act, DO HEREBY RESIGN. 

The Director of the corporation, by affixing his signature hereto, does hereby formally resign, and shall allow the new Board to choose its Directors at a time and place of its choosing.  

DATED:  May 25th, 2016

/s/ Josh Turner

Josh Turner, Director, CEO 

Zendex Holdings, Inc.axgn_Ex10_1_20160526

		
			Exhibit 10.1
		

		
			Amendment NO. 3 To Employment AGreement
		

		
			This Amendment No. 3 to Employment Agreement (this "Amendment") is entered into as of June 1, 2016 by and between Greg Freitag ("Freitag") and AXOGEN, INC. ("AxoGen").
		

		
			WHEREAS, Freitag and AxoGen entered into that certain Employment Agreement dated October 1, 2011, as amended (the "Agreement") for the employment of Freitag; and
		

		
			WHEREAS, Freitag has transitioned his duties as AxoGen CFO and continues his duties as General Counsel and Senior VP of Business Development; and
		

		
			WHEREAS, Freitag and AxoGen desire to amend the Agreement upon the terms and conditions hereinafter provided;
		

		
			NOW, THEREFORE, in consideration of the foregoing and for other consideration, the receipt and sufficiency of which are hereby acknowledged, Freitag and AXOGEN agree that the Agreement is hereby amended as follows:
		

		
			1.Capitalized terms used and not otherwise defined herein shall have the meanings ascribed to such terms in the Agreement.
		

		
			2.Schedule 1, Section 1 is replaced as follows:  AXOGEN hereby employs Employee as General Counsel and Senior Vice President of Business Development, which title may change at AXOGEN's discretion. 
		

		
			3.Schedule 1, Section 2. (a) is replaced as follows: Employee shall perform all duties in connection with Employee’s position, or as otherwise designated by AXOGEN, including, without limitation, the following duties: Provide support to AXOGEN and Corp. as to legal matters and business development activity, assist on all strategic and tactical matters as they relate to forecasting, financial structure and corporate development.
		

		
			4.Schedule 1, Section 2. (d) (i) is replaced as follows: Employee shall devote the time, energy and skill required for the performance of Employee’s duties pursuant to the Agreement, and as required by the CEO for the service of AXOGEN, and promotion of AXOGEN’s interests.  The Parties agree that Employee may not during Employee's employment, except as permitted in writing by AXOGEN, be engaged in any other business activity competitive with AXOGEN or which requires a time commitment that interferes with the duties of Employee.  AxoGen confirms and agrees that Employee is on the Board of Directors of PDS Biotechnology Corporation, on the Foundation Board of HealthEast Care System and is a principal in FreiMc, LLC. and EmployRx, LLC.  Employee hereby represents and warrants that such activity is not competitive with that of Employer and any activity associated with such organizations will not interfere with Employee’s performance of his duties for Employer.
		

		
			5.Schedule 2, Section 1 (a) is amended to provide that Base Salary will be $180,000.
		

		 

		

			 

		

 

		
			6.Schedule 2, Section 1. (d) is replaced as follows:  In addition to the Base Salary, Employee may also be eligible to receive stock options, benefits and holidays during Employee's Employment.
		

		
			7.Schedule 2, Section 6 (a), reference to AXOGEN bonus plan shall mean such bonus plan as established for the AXOGEN leadership team. 
		

		
			9.As amended hereby, the Agreement is hereby ratified and confirmed.
		

		
			IN WITNESS WHEREOF, the parties hereunto have executed this Amendment as of the date first written above.
		

			
					
						 

					
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						FREITAG:

				
	
					
						 

					
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						By:

					
					
						 

					
					
						/s/ Gregory Freitag

				
	
					
						 

					
					
						 

					
					
						 

					
					
						Gregory Freitag

				
	
					
						 

					
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						AXOGEN:

				
	
					
						 

					
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						AXOGEN, INC

				
	
					
						 

					
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						By:

					
					
						 

					
					
						/s/ Karen Zaderej

				
	
					
						 

					
					
						 

					
					
						 

					
					
						Name:   Karen Zaderej

				
	
					
						 

					
					
						Title:

					
					
						 

					
					
						CEO

				

		
			 
		

		 

		

			-  2  -qtnt-ex1038_86.htm

Exhibit 10.38

QBD(QS-IP)Limited

PO Box 1075, Elizabeth House, 9 Castle Street, St Helier, 

Jersey JE4 2PQ Channel Islands

 

 

March 28, 2016

 

The Technology Partnership plc

Melbourn Science Park, 

Melbourn, 

Hertfordshire  SG8 6EE

United Kingdom

Attention:  Dr. Sam Hyde, Managing Director

Dear Sirs, 

I write with reference to the Intellectual Property Rights Agreement made between The Technology Partnership plc (“TTP”) and QBD (QSIP) Limited (“QBD-IP”) made on March 4, 2014 (the “IPR Agreement”).  This letter records certain amendments to the IPR Agreement that we have agreed. By signing this letter I am agreeing to the revised terms set out in it on behalf of QBD-IP. If you agree these terms, please print and sign the PDF in the space provided and email it back to me.

We have agreed that the IPR Agreement shall be amended as follows:

	
1.
	
Under Section 2.11.2 the payment of USD$[***] due from QBD-IP to TTP on March 31, 2016 shall be deferred until the earlier of March 31, 2017 or 30 days following receipt of the first milestone payment from Ortho-Clinical Diagnostics, Inc. under our agreement with them dated January 29, 2015.

This amendment is made subject to all other provisions of the IPR Agreement.

Yours Sincerely, 

/s/ Paul Cowan

 

Paul Cowan

Chairman and CEO

QBD (QS-IP) Limited

 

 

Agreed by Dr. Sam Hyde, Managing Director, for and on behalf of The Technology Partnership plc.

 

/s/ Sam Hyde

...................................................

[***] CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00259-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00259-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00259-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00259-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00259-of-00352.parquet"}]]